» Articles » PMID: 19284549

Gz Mediates the Long-lasting Desensitization of Brain CB1 Receptors and is Essential for Cross-tolerance with Morphine

Overview
Journal Mol Pain
Date 2009 Mar 17
PMID 19284549
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the systemic administration of cannabinoids produces antinociception, their chronic use leads to analgesic tolerance as well as cross-tolerance to morphine. These effects are mediated by cannabinoids binding to peripheral, spinal and supraspinal CB1 and CB2 receptors, making it difficult to determine the relevance of each receptor type to these phenomena. However, in the brain, the CB1 receptors (CB1Rs) are expressed at high levels in neurons, whereas the expression of CB2Rs is marginal. Thus, CB1Rs mediate the effects of smoked cannabis and are also implicated in emotional behaviors. We have analyzed the production of supraspinal analgesia and the development of tolerance at CB1Rs by the direct injection of a series of cannabinoids into the brain. The influence of the activation of CB1Rs on supraspinal analgesia evoked by morphine was also evaluated.

Results: Intracerebroventricular (icv) administration of cannabinoid receptor agonists, WIN55,212-2, ACEA or methanandamide, generated a dose-dependent analgesia. Notably, a single administration of these compounds brought about profound analgesic tolerance that lasted for more than 14 days. This decrease in the effect of cannabinoid receptor agonists was not mediated by depletion of CB1Rs or the loss of regulated G proteins, but, nevertheless, it was accompanied by reduced morphine analgesia. On the other hand, acute morphine administration produced tolerance that lasted only 3 days and did not affect the CB1R. We found that both neural mu-opioid receptors (MORs) and CB1Rs interact with the HINT1-RGSZ module, thereby regulating pertussis toxin-insensitive Gz proteins. In mice with reduced levels of these Gz proteins, the CB1R agonists produced no such desensitization or morphine cross-tolerance. On the other hand, experimental enhancement of Gz signaling enabled an acute icv administration of morphine to produce a long-lasting tolerance at MORs that persisted for more than 2 weeks, and it also impaired the analgesic effects of cannabinoids.

Conclusion: In the brain, cannabinoids can produce analgesic tolerance that is not associated with the loss of surface CB1Rs or their uncoupling from regulated transduction. Neural specific Gz proteins are essential mediators of the analgesic effects of supraspinal CB1R agonists and morphine. These Gz proteins are also responsible for the long-term analgesic tolerance produced by single doses of these agonists, as well as for the cross-tolerance between CB1Rs and MORs.

Citing Articles

Preoperative Cannabis Use Did Not Increase Opioid Utilization After Primary Total Knee Arthroplasty in a Propensity Score-Matched Model.

Puri S, Ong C, Chiu Y, Lebowitz J, Sideris A, Gonzalez Della Valle A HSS J. 2024; 20(2):268-273.

PMID: 39281986 PMC: 11393616. DOI: 10.1177/15563316221151158.


Molecular basis of opioid receptor signaling.

Che T, Roth B Cell. 2023; 186(24):5203-5219.

PMID: 37995655 PMC: 10710086. DOI: 10.1016/j.cell.2023.10.029.


Mechanisms of cannabinoid tolerance.

Piscura M, Henderson-Redmond A, Barnes R, Mitra S, Guindon J, Morgan D Biochem Pharmacol. 2023; 214:115665.

PMID: 37348821 PMC: 10528043. DOI: 10.1016/j.bcp.2023.115665.


N-acylethanolamine regulation of TLR3-induced hyperthermia and neuroinflammatory gene expression: A role for PPARα.

Flannery L, Kerr D, Hughes E, Kelly C, Costello J, Thornton A J Neuroimmunol. 2021; 358:577654.

PMID: 34265624 PMC: 8243641. DOI: 10.1016/j.jneuroim.2021.577654.


Cannabinoids, Endocannabinoids and Sleep.

Kesner A, Lovinger D Front Mol Neurosci. 2020; 13:125.

PMID: 32774241 PMC: 7388834. DOI: 10.3389/fnmol.2020.00125.


References
1.
Martin B, Sim-Selley L, Selley D . Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci. 2004; 25(6):325-30. DOI: 10.1016/j.tips.2004.04.005. View

2.
Garzon J, Rodriguez-Diaz M, Lopez-Fando A, Garcia-Espana A, Sanchez-Blazquez P . Glycosylated phosducin-like protein long regulates opioid receptor function in mouse brain. Neuropharmacology. 2002; 42(6):813-28. DOI: 10.1016/s0028-3908(02)00027-8. View

3.
Mansour A, Khachaturian H, Lewis M, Akil H, Watson S . Anatomy of CNS opioid receptors. Trends Neurosci. 1988; 11(7):308-14. DOI: 10.1016/0166-2236(88)90093-8. View

4.
Tzavara E, Wade M, Nomikos G . Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci. 2003; 23(28):9374-84. PMC: 6740571. View

5.
Hohmann A, Suplita 2nd R . Endocannabinoid mechanisms of pain modulation. AAPS J. 2007; 8(4):E693-708. PMC: 2751366. DOI: 10.1208/aapsj080479. View